Cargando…

Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modeling

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Islam, Mohammad Mazharul, Goertzen, Andrea, Singh, Pankaj K., Saha, Rajib
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641750/ https://www.ncbi.nlm.nih.gov/pubmed/37965147 http://dx.doi.org/10.1016/j.isci.2023.108380

Ejemplares similares

Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modeling
por: Islam, Mohammad Mazharul, et al.
Publicado: (2022)

Investigation of microbial community interactions between Lake Washington methanotrophs using genome-scale metabolic modeling
por: Islam, Mohammad Mazharul, et al.
Publicado: (2020)

Correction: Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
Publicado: (2018)

Metabolic Pathways as a Novel Landscape in Pancreatic Ductal Adenocarcinoma
por: Ali, Ahmad, et al.
Publicado: (2022)

Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma
por: Ferguson, L. Paige, et al.
Publicado: (2023)

Metabolic Modeling Elucidates the Transactions in the Rumen Microbiome and the Shifts Upon Virome Interactions
por: Islam, Mohammad Mazharul, et al.
Publicado: (2019)

Transcriptional, chromatin, and metabolic landscapes of LDHA inhibitor–resistant pancreatic ductal adenocarcinoma
por: Malvi, Parmanand, et al.
Publicado: (2022)

Metabolism remodeling in pancreatic ductal adenocarcinoma
por: Li, Jin-Tao, et al.
Publicado: (2019)

Unsupervised subtyping and methylation landscape of pancreatic ductal adenocarcinoma
por: Roy, Shikha, et al.
Publicado: (2021)

Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
por: Pervin, Jannat, et al.
Publicado: (2023)

Markers of Bone Metabolism in Patients With Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma
por: Pezzilli, Raffaele, et al.
Publicado: (2015)

Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
por: Bailey, Peter, et al.
Publicado: (2016)

Correction to: Analysis of dynamic molecular networks for pancreatic ductal adenocarcinoma progression
por: Pan, Zongfu, et al.
Publicado: (2020)

Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma
por: Lau, Allison N, et al.
Publicado: (2020)

Targets (Metabolic Mediators) of Therapeutic Importance in Pancreatic Ductal Adenocarcinoma
por: Rai, Vikrant, et al.
Publicado: (2020)

Hyaluronan activated-metabolism phenotype (HAMP) in pancreatic ductal adenocarcinoma
por: Kudo, Yuzan, et al.
Publicado: (2019)

Molecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma Classification
por: Espiau-Romera, Pilar, et al.
Publicado: (2020)

Ubiquitous Aberration in Cholesterol Metabolism across Pancreatic Ductal Adenocarcinoma
por: Gunda, Venugopal, et al.
Publicado: (2022)

Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
por: Liu, Yu-Huei, et al.
Publicado: (2022)

Biological and Clinical Impacts of Glucose Metabolism in Pancreatic Ductal Adenocarcinoma
por: Liu, Zhao, et al.
Publicado: (2023)

Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma
por: Gautam, Shailendra K., et al.
Publicado: (2023)

Metabolic biomarkers for the differential diagnosis of pancreatic ductal adenocarcinoma vs. chronic pancreatitis
por: Mayerle, Julia, et al.
Publicado: (2014)

Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
por: Mayerle, Julia, et al.
Publicado: (2018)

The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma
por: Parkin, Ashleigh, et al.
Publicado: (2018)

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
por: Xu, He, et al.
Publicado: (2021)

The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma
por: Loch, Florian N., et al.
Publicado: (2023)

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
por: Ashok Kumar, Prashanth, et al.
Publicado: (2023)

Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma
por: Mahajan, Ujjwal Mukund, et al.
Publicado: (2021)

PTGES Expression Is Associated with Metabolic and Immune Reprogramming in Pancreatic Ductal Adenocarcinoma
por: Murthy, Divya, et al.
Publicado: (2023)

Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models
por: Hoare, Owen, et al.
Publicado: (2021)

Correction to: Nanotechnology-augmented sonodynamic therapy and associated immune-mediated effects for the treatment of pancreatic ductal adenocarcinoma
por: Hadi, Marym Mohammad, et al.
Publicado: (2023)

Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?
por: Ciernikova, Sona, et al.
Publicado: (2020)

The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification
por: Yang, Yefan, et al.
Publicado: (2022)

Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians
por: Piccardi, Margherita, et al.
Publicado: (2023)

Correction: Prorenin receptor acts as a potential molecular target for pancreatic ductal adenocarcinoma diagnosis
por: Arundhathi, Arivajiagane, et al.
Publicado: (2019)

Correction: Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma
por: Gruber, Elisabeth S., et al.
Publicado: (2020)

Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma
por: Gimotty, Phyllis A., et al.
Publicado: (2022)

Heterogeneity of metabolic adaptive capacity affects the prognosis among pancreatic ductal adenocarcinomas
por: Kanda, Taishu, et al.
Publicado: (2022)

Mitochondrial Metabolism in Pancreatic Ductal Adenocarcinoma: From Mechanism-Based Perspectives to Therapy
por: Padinharayil, Hafiza, et al.
Publicado: (2023)

Exploring the Tumor-Suppressing Potential of PSCA in Pancreatic Ductal Adenocarcinoma
por: Li, Kexin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gcpbkeeh6033s2js1i9apc5l09